Management of Anticoagulants and Antiplatelet Therapy in Atrial Fibrillation with Coronary Artery Disease

Introduction to Anticoagulant and Antiplatelet Therapy

The European Society of Cardiology recommends a time-limited triple therapy approach (oral anticoagulant + aspirin + clopidogrel) for 1-6 months depending on bleeding risk, followed by dual therapy (oral anticoagulant + clopidogrel) up to 12 months, then transition to oral anticoagulant monotherapy in patients with atrial fibrillation requiring anticoagulation who undergo coronary intervention 1, 2

For acute coronary syndrome with stent placement, high bleeding risk patients (HAS-BLED ≥3) should receive triple therapy for 1 month only (oral anticoagulant + aspirin ≤100mg + clopidogrel 75mg), followed by dual therapy for up to 12 months (oral anticoagulant + clopidogrel 75mg), and then oral anticoagulant monotherapy 1, 2
For elective PCI in stable coronary disease, triple therapy for 1 month (oral anticoagulant + aspirin ≤100mg + clopidogrel 75mg) is recommended, followed by dual therapy for up to 12 months (oral anticoagulant + clopidogrel 75mg), and then oral anticoagulant monotherapy 1

Direct oral anticoagulants (DOACs) are strongly preferred over warfarin due to lower bleeding risk with similar or superior efficacy, and the lowest FDA-approved dose effective for stroke prevention in atrial fibrillation should be used 1, 3
The American College of Cardiology recommends using the lowest FDA-approved dose effective for stroke prevention in atrial fibrillation when using DOACs in combination therapy 1, 3

Clopidogrel 75mg daily is the preferred P2Y12 inhibitor when combined with anticoagulation, and prasugrel or ticagrelor should be avoided as part of triple therapy unless there is a compelling indication 1, 3

Dual therapy (oral anticoagulant + clopidogrel) without aspirin may be considered as an alternative to initial triple therapy in selected patients, with a Class IIb recommendation, and may be particularly appropriate for patients at high bleeding risk 1, 3
The WOEST trial demonstrated lower bleeding rates with dual therapy versus triple therapy, no difference in myocardial infarction, stroke, target vessel revascularization, or stent thrombosis, and lower all-cause mortality at 1 year (2.5% vs 6.4%) with dual therapy 1, 3

A proton pump inhibitor (PPI) should be initiated prophylactically in all patients receiving combined anticoagulant and antiplatelet therapy to reduce gastrointestinal bleeding risk 2, 5

After 12 months, all antiplatelet therapy should be discontinued and oral anticoagulant monotherapy continued based on CHA2DS2-VASc score 2, 4, 5

Dual antiplatelet therapy alone (without anticoagulation) should not be used in patients with moderate-to-high CHA2DS2-VASc scores, as this inadequately addresses stroke risk 2
Triple therapy should not be prolonged beyond recommended durations, as bleeding risk substantially outweighs any marginal thrombotic benefit 1, 2
Antiplatelet therapy should not be continued beyond 12 months in stable patients with chronic coronary disease who require oral anticoagulation, as this increases bleeding risk without reducing ischemic events 4

Post-CABG patients with atrial fibrillation should continue dual therapy (oral anticoagulant + clopidogrel) for 12 months, and then discontinue clopidogrel and continue oral anticoagulant monotherapy 4, 5
For intubated patients or those unable to take oral medications, parenteral anticoagulation (unfractionated heparin or LMWH) within 24 hours of PCI (low bleeding risk) or 48-72 hours (high bleeding risk) is recommended, or alternatively, crushed tablets may be considered 6